Pharmaceutical Technology

SEPTEMBER 15, 2022

Research by GlobalData (Contract Small Molecule API Manufacturing Industry by the Numbers – 2021 Edition) shows that containment facilities are in high demand as the use of cytotoxic drugs continues to grow. This adds costs and time to the processes involved.

Containment 130

Containment Manufacturing Production Contract Manufacturing 130

Pharmaceutical Technology

DECEMBER 6, 2022

Manufacturing these highly potent and often cytotoxic drugs introduces many risks for operators and the environment. Cross-contamination of standard products with highly potent ones is another key concern. Many companies are now prioritising investments in containment systems, GlobalData research shows.

Containment 130

Containment Development Drugs Contract Manufacturing 130

Roots Analysis

OCTOBER 24, 2023

Owing to the advancement in clinical pharmacology and oncology domain, and the rising demand for targeted therapeutics and precision medicines, high potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs have become one of the key areas of interest to researchers and drug manufacturers across the globe.

Manufacturing 40

Manufacturing Hormones Contamination Containment 40

Pharmaceutical Technology

JANUARY 12, 2023

Research Associate III, who is a parenteral fill/finish and lyophilization specialist at Baxter BioPharma Solutions (BPS) – a business unit of Baxter Healthcare, Inc. Why is continuing research so important? Pharmaceutical Technology spoke with Kevin Bond Ph.D., What are the key advantages of this stabilization method?

Production 130

Production Contamination Development Manufacturing 130

FDA Law Blog

JANUARY 1, 2024

The letter also stated that the company’s response to the inspection report was “inadequate because it did not include a review of environmental monitoring data in your manufacturing areas, an adequate risk analysis of previously manufactured drug product, or testing of reserve samples from impacted batches.” Dextrum Laboratories Inc.

Manufacturing 59

Manufacturing Production Drugs Contract Manufacturing 59

The Pharma Data

MAY 4, 2021

billion, primarily driven by Pfizer CentreOne, Pfizer’s contract manufacturing operation, reflecting sales of legacy Upjohn products to Viatris (4) and remdesivir to Gilead Sciences Inc., Clinical and Research Developments. Current 2021 financial guidance is presented below. . . down 7%, which reflects relatively stable U.S.

Vaccination 40

Vaccination Vaccine Production Sales 40